【Bionime】Announcement: Company's "RIGHTEST iFree2 Continuous Glucose Monitoring System (CGM)" Obtains Class II Medical Device Approval Notice from Taiwan Food and Drug Administration (TFDA)
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Bionime Corporation announced that its second-generation continuous glucose monitoring system, "RIGHTEST iFree2 CGM," has received Class II medical device approval from the Taiwan Food and Drug Administration (TFDA). This system is designed to help diabetic patients aged 18 to 80 manage their blood sugar.